Conference call details
Date: Thursday, November 5, 2009 Time: 9:00 a.m. ET Conference Call Numbers Domestic: 866-770-7125 International: 617-213-8066 Participant Passcode: 76724058 Web cast: http://www.arqule.com
A replay of the conference call will be available beginning at 12:00 p.m. on November 5, 2009 for seven days and can be accessed by dialing toll-free 888-286-8010 and outside the U.S. 1-617-801-6888. The access code is 86035092.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-MET receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. An additional clinical-stage program includes compounds that activate the cell's DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company's pre-clinical pipeline includes a compound designed to inhibit the BRAF kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)) are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
SOURCE: ArQule
ArQule William B. Boni, 781-994-0300 VP, Investor Relations/ Corp. Communications www.ArQule.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index